SYnAbs generates innovative monoclonal antibodies against:
SYnAbs unique technologies (SYnDNA vector, SYnCell syngeneic cell, in-house adjuvant) coupled with its strong expertise in breaking immune tolerance in proprietary rat-LOU species, ensure the generation of high specificity and higher affinity antibodies, benefiting from natural in-vivo maturation and targeting epitopes that are difficult to express in their native and functionally active conformation.
The application of such technologies have led, among others, to the generation of numerous functional therapeutic antibodies like :
Mar. 20th - Mar. 22nd
Apr. 14th - Apr. 19th
May 10th - May 12th
June 5th - June 8th
Oct 10th - Oct 12th
Oct 12th - Oct 14th
Oct 20th - Oct 24th
Nov 1st - Nov 5th
Nov 6th - Nov 8th
Nov 14th - Nov 16th
Nov 15th - Nov 18th
Dec 12th - Dec 13th
BioEurope Spring, Basel
AACR, Orlando
Bio Korea, Seoul
BIO International, Boston
Festival of Biologics, Basel
BioJapan, Yokohama
ESMO, Madrid
SITC, San Diego
BioEurope Fall, Munich
PEGS
Medica
BioFIT
A flexible, cost-effective platform developed for the discovery of novel compounds (protein degraders)
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
BE 0637.716.206